Home Cart Sign in  
Chemical Structure| 536-59-4 Chemical Structure| 536-59-4

Structure of Perillyl alcohol
CAS No.: 536-59-4

Chemical Structure| 536-59-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Perillyl Alcohol is a naturally occurring monocyclic terpene which can inhibit farnesyl transferase and geranylgeranyl transferase.

Synonyms: Isocarveol; Perilla alcohol

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Perillyl alcohol

CAS No. :536-59-4
Formula : C10H16O
M.W : 152.23
SMILES Code : OCC1=CCC(C(C)=C)CC1
Synonyms :
Isocarveol; Perilla alcohol
MDL No. :MFCD00001567
InChI Key :NDTYTMIUWGWIMO-UHFFFAOYSA-N
Pubchem ID :10819

Safety of Perillyl alcohol

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00910884 - Not yet recruiting February 2020 United States, Washington ... More >> Brabant Research, Incorporated Not yet recruiting Spokane Valley, Washington, United States, 99216 Contact: Richard E. Lasker, PhD    509-340-9902    rel@brabantresearch.com Less <<
NCT02704858 Glioblastoma Multiforme Phase 1 Phase 2 Recruiting October 2020 United States, California ... More >> University of Southern California Recruiting Los Angeles, California, United States, 90033 Contact: Aida Lozada    323-865-3980    Aida.Lozada@med.usc.edu    Principal Investigator: Naveed Wagle, MD          United States, Florida Cleveland Clinic Florida Not yet recruiting Weston, Florida, United States, 33331 Contact: Abel Rodriguez    954-487-2258    rodriga2@ccf.org    Principal Investigator: Bruno Bastos, MD          United States, Ohio Cleveland Clinic Recruiting Cleveland, Ohio, United States, 44333 Contact: Teresa Allison    216-444-6459    allisot@ccf.org    Contact: Theresa Naska    216-444-8923    naskat@ccf.org    Principal Investigator: David Peereboom, MD          United States, Washington University of Washington Seattle Cancer Care Alliance Recruiting Seattle, Washington, United States, 98109 Contact: Ana Valeria Martin    206-221-1538    avmartin@uw.edu    Contact: Bryan Kim    206-543-4069    bkim500@uw.edu    Principal Investigator: Lynne Taylor, MD          United States, Wisconsin University of Wisconsin Hospital and Clinic Recruiting Madison, Wisconsin, United States, 53792 Contact: Diana Trask    608-263-9528    trask@humonc.wisc.edu    Contact: Belinda BuehlSoppe    608-265-9958    bkbuehl@humonc.wisc.edu    Principal Investigator: Steve Howard, MD Less <<
NCT00022425 Breast Cancer Phase 1 Unknown - United States, Ohio ... More >> Cleveland Clinic Taussig Cancer Center Cleveland, Ohio, United States, 44195-9001 Less <<
NCT00003219 Breast Cancer Phase 2 Completed - United States, Wisconsin ... More >> University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin, United States, 53792 Less <<
NCT00608634 Precancerous Condition Phase 2 Completed - United States, Arizona ... More >> Arizona Cancer Center at University of Arizona Health Sciences Center Tucson, Arizona, United States, 85724-5024 Less <<
NCT00003769 Pancreatic Cancer Phase 2 Completed - United States, Indiana ... More >> Indiana University Cancer Center Indianapolis, Indiana, United States, 46202-5289 Less <<
NCT00608634 - Completed - -
NCT00002862 Lymphoma Unsp... More >>ecified Adult Solid Tumor, Protocol Specific Less << Phase 1 Completed - United States, Connecticut ... More >> Yale Comprehensive Cancer Center New Haven, Connecticut, United States, 06520-8028 Less <<
NCT00003238 Prostate Cancer Phase 2 Completed - United States, Illinois ... More >> Leonard C. Ferguson Cancer Center Freeport, Illinois, United States, 61032 United States, Wisconsin Green Bay Oncology, Ltd. Green Bay, Wisconsin, United States, 54307-3453 Mercy Health System Janesville, Wisconsin, United States, 53545 Gundersen Lutheran Medical Center La Crosse, Wisconsin, United States, 54601 Meriter Hospital Madison, Wisconsin, United States, 53715 University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin, United States, 53792 Sinai Samaritan Medical Center - Milwaukee Milwaukee, Wisconsin, United States, 53201-0342 North Central Oncology Associates, S.C. Wausau, Wisconsin, United States, 54401 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

6.57mL

1.31mL

0.66mL

32.85mL

6.57mL

3.28mL

65.69mL

13.14mL

6.57mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories